The Breast Friends Podcast – Details, episodes & analysis

It’s finally here. 🎙️

The first full episode of The Breast Friends Podcast is live. Join Dr. Jason A. Mouabbi and Dr. Paolo Tarantino for a comprehensive look at the rapidly evolving breast cancer landscape. From new endocrine backbones to the "unprecedented" data emerging in the ADC space, they are debating the breakthroughs that are changing the way we practice medicine today.

Beyond the statistics, this episode focuses on the "art" of clinical selection. You’ll hear an honest discussion on therapy sequencing, balancing toxicities, and navigating complex trial data—all while ensuring treatment is tailored to each patient’s unique needs and daily reality.

Real data. Hard questions. And yes—plenty of fun along the way.

#BreastCancer #OncologyPodcast #CancerCare #MedicalOncology #BreastCancerResearch #MedEd #ClinicalOncology #PhysicianVoices

It’s about time.

Introducing The Breast Friends Podcast—a new podcast where cutting-edge breast cancer science meets real friendship.

Hosted by Dr. Jason Mouabbi, your “best-friend oncologist,” and joined by Dr. Paolo Tarantino, this podcast dives into the data behind today’s biggest treatment advances, real-world outcomes, and the conversations clinicians actually have behind the scenes.

Serious science. Real insight. And yes—plenty of fun along the way.

Because progress is better when you talk it through with a friend.

Watch. Listen. Join the conversation.

#TheBreastFriendsPodcast #BreastCancer #OncologyPodcast #CancerCare #BreastCancerResearch #MedicalPodcast #OncologyCommunity #CancerResearch #MedEd #PhysicianVoices #ClinicalOncology #HealthcareInnovation #ScienceMeetsHumanity

What’s coming in 2026 is about to reshape breast oncology.

In Episode 2, Dr. Jason Mouabbi and Dr. Paolo Tarantino go beyond published data to tackle the tough questions about what's next. They break down the evolving landscape of KEYNOTE-756, the rise of oral SERDs in the first line, and the role of HER2DX. From T-DXd in early disease and CNS risk in HER2+, to the promise of improving outcomes in triple-negative breast cancer, they are laying out the roadmap for the future of care.

The landscape is moving fast. Listen in as we prepare for the next wave of practice-changing data.

▶️ Watch on YouTube - https://youtu.be/Skt3jGMBncM

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox, & Amazon Music

#BreastCancer #Oncology #OncologyPodcast #ClinicalTrials #CancerResearch #HER2Positive #TripleNegative #OralSERD #ADCs #MedicalOncology #MedEd #CancerCare

👉 Cast your vote here: https://www.tinyurl.com/breastfriendsmadness

It’s March Madness, the Breast Friends Madness way!

In Episode 3, Dr. Jason Mouabbi and Dr. Paolo Tarantino are hitting the court to break down the heavy hitters of 2025 using our "Breast Friends Madness" bracket.

Among the featured lineups are studies ranging from the practice-changing results of the DESTINY-Breast trials to the strategic shifts in SERENA-6, monarchE, and ASCENT-04. We’re scouting the data officially rewriting the playbook for HER2+, TNBC, and HR+ care.

EVERY study in this bracket is a WIN for our patients. Let’s get ready to highlight the trials moving the field forward.

▶️ Watch on YouTube

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox & Amazon Music

#BreastCancer #Oncology #OncologyPodcast #CancerResearch #ClinicalTrials #HER2Positive #TripleNegativeBreastCancer #MedEd #MedicalOncology

What does the future of breast oncology look like?

In Episode 4, Dr. Jason Mouabbi and Dr. Paolo Tarantino are joined by Professor Giuseppe Curigliano, Professor of Medical Oncology at the University of Milano, Head of the Experimental Therapeutics Program at the European Institute of Oncology, ESMO President-Elect, and Young Science Talent Scout, to forecast the next decade of breast cancer care.

This conversation looks beyond current standards to the next frontier of breast oncology—from the evolution of ADCs and ctDNA to the emerging roles of bispecifics, radioligand therapy, and cancer vaccines.

We’re mapping out where the science is heading and how it will redefine precision medicine in breast cancer!

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music

#BreastCancer #Oncology #OncologyPodcast #CancerResearch #ClinicalTrials #PrecisionMedicine #MedEd #MedicalOncology #ESMO #CancerInnovation

What shaped modern breast oncology and what comes next?

From the pioneering HER2 breakthroughs to the recent innovation of ADCs and oral SERDs, Dr. Rugo provides a masterclass on the therapies that are changing the standard of care. The discussion also looks ahead, exploring the clinical utility of ctDNA monitoring and the critical importance of preserving quality of life in the metastatic setting.

From HER2 breakthroughs and ADC innovation to oral SERDs, ctDNA monitoring, quality of life, and the future of metastatic breast cancer care, this conversation is a masterclass in where the field has been and where it’s heading next.

This is oncology history, innovation, and the future all in one conversation.

🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino

👤 Featuring Dr. Hope Rugo

▶️ Watch on YouTube - https://youtu.be/IGbXzLpE-LY

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music

#BreastCancer #Oncology #OncologyPodcast #HopeRugo #CancerResearch #ClinicalTrials #PrecisionMedicine #MedicalOncology #MedEd #ADC

The HER2-positive revolution isn't coming. It's here.

In Episode 6 of The Breast Friends Podcast, Dr. Jason Mouabbi and Dr. Paolo Tarantino unpack the practice-changing data emerging from ESMO Breast 2026.

From DESTINY-Breast11 and DESTINY-Breast05 to the growing role of HER2DX, ctDNA, MRI-guided treatment adaptation, and chemotherapy-free strategies, this conversation explores a fundamental shift in breast oncology: moving from treating every patient the same to delivering truly personalized care.

Can we safely eliminate carboplatin?

Can biomarkers tell us who needs less treatment?

Is a chemotherapy-free future finally a reality for certain patients?

The future of HER2-positive breast cancer is being written right now.

🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino

▶️ Watch on YouTube - https://youtu.be/WrvmVGEgoIA

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music

#BreastCancer #HER2Positive #Oncology #OncologyPodcast #ESMOBreast #CancerResearch #ClinicalTrials #PrecisionMedicine #MedicalOncology #MedEd #Enhertu #TDXd